21 patents
Utility
Carbocyclic prolinamide derivatives
9 Jan 24
This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye.
Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
Filed: 14 Jul 21
Utility
Method for Treating or Preventing Idiopathic Polypoidal Choroidal Vasculopathy (Ipcv)
4 Jan 24
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-C5 agent) and Eylea® (or another VEGF antagonist).
Kourous Rezaei
Filed: 8 Feb 23
Utility
Methods for Treating Ophthalmological Conditions
14 Dec 23
The present invention relates to methods for treating a subject with risk factors for progression to iRORA, iRORA, nGA, cRORA, GA, AMD, intermediate AMD, dry AMD, and/or wet AMD, in a subject in need thereof comprising administration of an effective amount of an anti-C 5 agent or a pharmaceutically acceptable salt thereof.
Pravin Dugel, Dhaval B. Desai
Filed: 31 Oct 21
Utility
Methods for Treating or Preventing Ophthalmological Conditions
16 Nov 23
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof.
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Filed: 7 Apr 23
Utility
Methods for Treating or Preventing Ophthalmological Conditions
16 Nov 23
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof.
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Filed: 7 Apr 23
Utility
ANTI-C5 Agent for Treatment of Dry Age-related Macular Degeneration (Amd) or Geographic Atrophy Secondary to Dry Amd
14 Sep 23
This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration.
Kourous A. Rezaei
Filed: 7 Apr 23
Utility
Method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
7 Mar 23
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-C5 agent) and Eylea® (or another VEGF antagonist).
Kourous Rezaei
Filed: 16 Nov 18
Utility
ANTI-C5 Agent for Treatment of Dry Age-related Macular Degeneration (Amd) or Geographic Atrophy Secondary to Dry Amd
24 Nov 22
This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration.
Kourous A. Rezaei
Filed: 26 Oct 20
Utility
Methods for treating or preventing ophthalmological conditions
8 Nov 22
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof.
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Filed: 21 Feb 22
Utility
Heterocyclic Prolinamide Derivatives
25 Aug 22
Robert Gomez, Jinyue Ding, Renata Oballa, David Andrew Powell, Maxim Epifanov
Filed: 6 May 22
Utility
Heterocyclic prolinamide derivatives
5 Jul 22
Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell, Maxim Epifanov
Filed: 15 Jun 17
Utility
Methods for Treating or Preventing Ophthalmological Conditions
9 Jun 22
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof.
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Filed: 21 Feb 22
Utility
Methods for treating or preventing ophthalmological conditions
15 Mar 22
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof.
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Filed: 14 Jun 21
Utility
Carbocyclic prolinamide derivatives
8 Mar 22
This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye.
Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
Filed: 6 Jan 20
Utility
Methods for Treating or Preventing Ophthalmological Conditions
2 Dec 21
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof.
Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Filed: 14 Jun 21
Utility
Carbocyclic Prolinamide Derivatives
11 Nov 21
This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye.
Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
Filed: 14 Jul 21
Utility
Carbocyclic prolinamide derivatives
17 Aug 21
This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye.
Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
Filed: 6 Jan 20
Utility
a Method for Treating or Preventing Idiopathic Polypoidal Choroidal Vasculopathy (Ipcv)
10 Jun 21
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-CS agent) and Eylea® (or another VEGF antagonist).
Kourous Rezaei
Filed: 16 Nov 18
Utility
Carbocyclic Prolinamide Derivatives
9 Dec 20
This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye.
Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
Filed: 5 Jan 20
Utility
Aliphatic prolinamide derivatives
3 Aug 20
Austin Chih-Yu Chen, Robert Gomez, Renata Marcella Oballa, David Andrew Powell, Jeffrey Roger Roppe, Thomas Jon Seiders, Tao Sheng
Filed: 14 Jun 17